4000 Shoreline Court
Suite 300
South San Francisco, CA 94080
United States
650 822 5600
https://www.kezarlifesciences.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 58
Nombre | Título | Paga | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Dr. Christopher J. Kirk Ph.D. | Co-Founder, CEO & Director | 677,41k | N/A | 1973 |
Mr. John Franklin Fowler | Co-Founder & Director | 919,91k | N/A | 1972 |
Dr. Jack Taunton Ph.D. | Co-Founder | N/A | N/A | N/A |
Mr. Marc L. Belsky | CFO & Secretary | 491,79k | N/A | 1955 |
Ms. Gitanjali Jain | Vice President of Investor Relations & External Affairs | N/A | N/A | N/A |
Mr. Mark Schiller | Chief Legal Officer | N/A | N/A | N/A |
Dr. Neel K. Anand Ph.D. | Senior Vice President of Research & Drug Discovery | N/A | N/A | N/A |
Dr. Nick Mordwinkin Ph.D., Pharm.D. | Chief Business Officer & Head of Strategy | N/A | N/A | 1981 |
Mr. Zung To | Senior Vice President of Clinical Development | N/A | N/A | N/A |
Ms. Pattie Chiang | VP & Corporate Controller | N/A | N/A | N/A |
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
El ISS Governance QualityScore de Kezar Life Sciences, Inc., a día 1 de marzo de 2024, es 9. Las puntuaciones base son Auditoría: 7; Tablero: 7; Derechos de los accionistas: 8; Compensación: 9.